Product image of Insuman Implantable (Insulin Human) supplied by GNH India

Insuman Implantable

Active Ingredient:
Insulin Human
Origin:
EU

Insuman Implantable (Insulin Human)

Insulin Human, the active ingredient in Insuman Implantable, is a peptide hormone presented as an implantable formulation for intraperitoneal use. It replaces deficient endogenous insulin and helps regulate blood glucose levels in patients with diabetes mellitus. It is indicated for long‑term glycemic control in type 1 and type 2 diabetes when other routes are unsuitable.

GNH India supplies Insuman Implantable as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Manufacturer / TM Owner

Sanofi-Aventis Deutschland Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Insuman Implantable (Insulin Human) acts on the insulin signaling pathway to manage diabetes mellitus.

  • Type 1 Diabetes: provides basal insulin replacement to maintain glucose homeostasis.
  • Type 2 Diabetes: supplements endogenous insulin when pancreatic function is insufficient.
  • Gestational Diabetes: helps achieve target glucose levels when diet alone is inadequate.

How It Works

  • Insulin Human binds to the insulin receptor on cell membranes, activating the receptor’s intrinsic tyrosine‑kinase activity. This triggers downstream signaling cascades that promote translocation of GLUT‑4 transporters to the cell surface, enhancing glucose uptake in muscle and adipose tissue while suppressing hepatic glucose production, thereby lowering blood glucose concentrations.

Side Effects

Adverse reactions may occur with any insulin therapy.

Common Side Effects

  • Hypoglycemia: symptoms of low blood sugar such as sweating, tremor, or confusion.
  • Injection‑site reactions: redness, swelling, or pain at the implant site.
  • Weight gain: increased adipose tissue due to improved glucose utilization.
  • Edema: mild fluid retention, especially in the lower extremities.

Serious or Rare Side Effects

  • Severe hypoglycemia leading to seizures or loss of consciousness.
  • Allergic reactions: rash, urticaria, or anaphylaxis.
  • Insulin antibodies: may alter insulin action or cause delayed hypersensitivity.
  • Lipodystrophy: abnormal fat distribution at the implant site.
  • Hypokalemia: low potassium levels secondary to rapid glucose shifts.

Precautions & Warnings

Patients and clinicians should observe several safety measures when using Insuman Implantable.

  • Dose individualization: adjust dosage based on regular blood‑glucose monitoring and clinical response.
  • Hypoglycemia risk: educate patients to recognize early signs and have rapid‑acting carbohydrate available.
  • Renal impairment: consider dose reduction as insulin clearance may be decreased.
  • Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Avoid Interactions

Insuman Implantable may interact with other medications, requiring careful management.

Major Interactions (Avoid)

  • Beta‑blockers: can mask hypoglycemia symptoms, making detection difficult.
  • Oral sulfonylureas: additive glucose‑lowering effect increases risk of severe hypoglycemia.
  • MAO inhibitors: may potentiate insulin’s glucose‑lowering action.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors: may enhance insulin sensitivity, necessitating dose review.
  • Thiazide diuretics: can raise blood glucose levels, potentially requiring higher insulin doses.
  • Corticosteroids: increase insulin resistance, often demanding dose adjustments.

Frequently Asked Questions

Insuman Implantable is an implantable insulin formulation that provides long‑acting basal insulin to help control blood glucose levels in patients with diabetes mellitus, including type 1, type 2, and gestational diabetes when other delivery routes are unsuitable.

Insulin Human mimics the body’s natural insulin by binding to insulin receptors on cell surfaces, activating a cascade that moves glucose‑transport proteins to the cell membrane, thereby increasing glucose uptake into muscle and fat cells and reducing hepatic glucose production.

The appropriate dose of Insuman Implantable is determined individually by a qualified prescriber based on the patient’s blood‑glucose readings, body weight, type of diabetes, and overall treatment plan. No fixed regimen is provided publicly.

Safety data for Insuman Implantable in pregnancy and lactation are limited. It should be used only if the expected benefit to the mother outweighs any potential risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Unlike conventional subcutaneous insulin injections, Insuman Implantable delivers insulin intraperitoneally from a long‑acting implant, offering a more stable basal level and potentially fewer injection‑site complications. However, it requires surgical placement and specific storage conditions, which differ from standard insulin pens or vials.

Insuman Implantable must be stored at 2‑8 °C in a refrigerator, protected from light. It should never be frozen or shaken. Keep the product in its original packaging until use and follow any additional handling instructions provided by the supplier.

The product is implanted intraperitoneally by a qualified healthcare professional using a minimally invasive surgical technique. Once placed, the implant releases insulin continuously over an extended period, eliminating the need for daily injections.

The most serious risks include severe hypoglycemia that can lead to seizures or loss of consciousness, allergic reactions such as anaphylaxis, and the formation of insulin antibodies that may alter insulin effectiveness. Prompt medical attention is required if any of these occur.

Patients with a known hypersensitivity to insulin Human or any component of the implant formulation should avoid using Insuman Implantable. It is also contraindicated in individuals with uncontrolled infections at the implantation site or those for whom intraperitoneal surgery is medically inadvisable.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Insulin Human

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT